Impact of Serum Cystatin C Level on Long-Term Cognitive Impairment After Acute Ischemic Stroke and Transient Ischemic Attack
Lijun Zuo,Yanhong Dong,Yuesong Pan,Hongyi Yan,Xia Meng,Hao Li,Xingquan Zhao,Yilong Wang,Yongjun Wang,Xiaoling Liao
DOI: https://doi.org/10.2147/NDT.S412825
IF: 2.989
2023-07-06
Neuropsychiatric Disease and Treatment
Abstract:Lijun Zuo, 1 Yanhong Dong, 2 Yuesong Pan, 3 Hongyi Yan, 3 Xia Meng, 3 Hao Li, 3 Xingquan Zhao, 1 Yilong Wang, 1 Yongjun Wang, 1 Xiaoling Liao 1 1 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Clinical Research Centre, Singapore, 117597, Singapore; 3 National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Xiaoling Liao, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China, Tel +86-010-59978350, Fax +86-010-59973383, Email Objective: Cognitive impairment after stroke/transient ischemic attack (TIA) has a high prevalence. Cystatin C (CysC) has been found as a novel biomarker of neurodegenerative diseases, such as dementia and Alzheimer's disease. We aimed to explore the possible correlations of serum CysC level with cognitive impairment in patients who had mild ischemic stroke and TIA after 1 year. Methods: We measured serum CysC level in 1025 participants with a minor ischemic stroke/TIA from enrolled from the Impairment of Cognition and Sleep (ICONS) study of the China National Stroke Registry-3 (CNSR-3). They were divided into four groups according to quartiles of baseline CysC levels. Patients' cognitive functions were assessed by Montreal Cognitive Assessment (MoCA)-Beijing at day 14 and at 1 year. Multiple logistic regression models were performed to evaluate the relationship between CysC and post-stroke cognitive impairment (PSCI) at 1-year follow-up. Results: Cognitive impairment was defined as MoCA-Beijing ≤ 22. Most patients were in 60s (61.52± 10.97 years old) with a median (interquartile range) National Institute of Health Stroke Scale(NIHSS) score of 3.00 (4.00) and greater than primary school level of education, and 743 participants (72.49%) were male. Among the 1025 participants, 331 participants (32.29%) patients suffered PSCI at 1-year follow-up. A U-shaped association was observed between CysC and 1-year PSCI [quartile (Q)1 vs Q3: adjusted odds ratio (aOR) 2.69, 95% CI 1.67– 4.34, p < 0.0001; Q2 vs Q3: aOR 1.63, 95% CI 1.03– 2.57, p = 0.0354; Q4 vs Q3: aOR 1.83, 95% CI 1.16– 2.87, p = 0.009]. Moreover, the U-shaped trends were also found between CysC level and the subscores of attention, recall, abstraction and language in MoCA. Conclusion: CysC showed a U-shaped correlation with 1-year overall cognitive function. It is probable that measurement of the serum CysC level would aid in the early diagnosis of PSCI. Keywords: mild stroke, post stroke cognitive impairment, cystatin C Long-term cognitive impairment is a common complication of acute ischemic stroke (AIS)/transient ischemic attack (TIA). Although neurological deficits may return to a certain extent (transient cognitive impairment [TCI]), cognitive recovery does not necessarily consistent with physical recovery. About 40% of patients had a TCI within 7 days after TIA compared to only 19% of those seen after 7 days. 1 There are both transient and long-term cognitive impairment after TIA. 2 This TCI (rather than the absolute cognitive level) predicted subsequent cognitive decline. Approximately 58.82% of patients experienced cognitive impairment after stroke in acute phase. 3 It may affect the quality of life, and predict dependency 4 and death. 5 Cystatin C (CysC) is an endogenous protein inhibitor of cysteine protease. It plays a wide range of biological roles, ranging from regulating normal tissue processes such as cell proliferation and growth to modulating potentially pathogenic events, including infection, 6 and neurodegenerative diseases such as dementia, Alzheimer's disease (AD). 7 CysC was reported as a predictive marker of cardiovascular diseases 8 and AIS. 9 CysC has been thought to be related to the clinical manifestations of cognitive impairment. 10–12 There have been several studies demonstrating that CysC inhibited the aggregation of cerebral amyloid protein (Aβ) and potentially prevented cognitive impairment in AD. 13 It indicated that low level of CysC combined with increased cysteines protease and amyloid protein aggregation, 14 which has direct cytotoxic effects on brain tissue and leads to cognitive impairment. 15 On the other hand, cohort studies evaluated the associa -Abstract Truncated-
psychiatry,clinical neurology